OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease
Tanya Simuni, Brian Fiske, Kalpana Merchant, et al.
JAMA Neurology (2020) Vol. 78, Iss. 3, pp. 312-312
Open Access | Times Cited: 111
Tanya Simuni, Brian Fiske, Kalpana Merchant, et al.
JAMA Neurology (2020) Vol. 78, Iss. 3, pp. 312-312
Open Access | Times Cited: 111
Showing 1-25 of 111 citing articles:
The Genetics of Parkinson’s Disease and Implications for Clinical Practice
Jacob Day, Stephen Mullin
Genes (2021) Vol. 12, Iss. 7, pp. 1006-1006
Open Access | Times Cited: 152
Jacob Day, Stephen Mullin
Genes (2021) Vol. 12, Iss. 7, pp. 1006-1006
Open Access | Times Cited: 152
Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities
Bruna Araújo, Rita Caridade-Silva, Carla Guedes, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2908-2908
Open Access | Times Cited: 85
Bruna Araújo, Rita Caridade-Silva, Carla Guedes, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2908-2908
Open Access | Times Cited: 85
Medical, surgical, and physical treatments for Parkinson's disease
Thomas Foltynie, Verónica Bruno, Susan H. Fox, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 305-324
Open Access | Times Cited: 73
Thomas Foltynie, Verónica Bruno, Susan H. Fox, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 305-324
Open Access | Times Cited: 73
The KEAP1-NRF2 System and Neurodegenerative Diseases
Akira Uruno, Masayuki Yamamoto
Antioxidants and Redox Signaling (2023) Vol. 38, Iss. 13-15, pp. 974-988
Closed Access | Times Cited: 58
Akira Uruno, Masayuki Yamamoto
Antioxidants and Redox Signaling (2023) Vol. 38, Iss. 13-15, pp. 974-988
Closed Access | Times Cited: 58
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
Kevin McFarthing, Susan Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 4, pp. 427-439
Open Access | Times Cited: 54
Kevin McFarthing, Susan Buff, Gary Rafaloff, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 4, pp. 427-439
Open Access | Times Cited: 54
Novel targeted therapies for Parkinson’s disease
Theodora Ntetsika, Paraskevi-Evita Papathoma, Ioanna Markaki
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 78
Theodora Ntetsika, Paraskevi-Evita Papathoma, Ioanna Markaki
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 78
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease
Hilary Grosso Jasutkar, Stephanie Oh, M. Maral Mouradian
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 207-237
Open Access | Times Cited: 68
Hilary Grosso Jasutkar, Stephanie Oh, M. Maral Mouradian
Pharmacological Reviews (2022) Vol. 74, Iss. 1, pp. 207-237
Open Access | Times Cited: 68
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
Noha Gouda, Ahmed Elkamhawy, Jungsook Cho
Biomedicines (2022) Vol. 10, Iss. 2, pp. 371-371
Open Access | Times Cited: 57
Noha Gouda, Ahmed Elkamhawy, Jungsook Cho
Biomedicines (2022) Vol. 10, Iss. 2, pp. 371-371
Open Access | Times Cited: 57
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
Shirley Yin-Yu Pang, Rachel Lo, Philip Wing‐Lok Ho, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
Shirley Yin-Yu Pang, Rachel Lo, Philip Wing‐Lok Ho, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
Recent Advances in Drug Therapy for Parkinson's Disease
Hidetomo Murakami, Tomotaka Shiraishi, Tadashi Umehara, et al.
Internal Medicine (2022) Vol. 62, Iss. 1, pp. 33-42
Open Access | Times Cited: 38
Hidetomo Murakami, Tomotaka Shiraishi, Tadashi Umehara, et al.
Internal Medicine (2022) Vol. 62, Iss. 1, pp. 33-42
Open Access | Times Cited: 38
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease
Thomas Payne, Matthew Appleby, Ellen Buckley, et al.
Movement Disorders (2023) Vol. 38, Iss. 8, pp. 1493-1502
Open Access | Times Cited: 27
Thomas Payne, Matthew Appleby, Ellen Buckley, et al.
Movement Disorders (2023) Vol. 38, Iss. 8, pp. 1493-1502
Open Access | Times Cited: 27
Drug repositioning for Parkinson’s disease: an emphasis on artificial intelligence approaches
Iman Karimi-Sani, Mehrdad Sharifi, Nahid Abolpour, et al.
Ageing Research Reviews (2025) Vol. 104, pp. 102651-102651
Closed Access | Times Cited: 1
Iman Karimi-Sani, Mehrdad Sharifi, Nahid Abolpour, et al.
Ageing Research Reviews (2025) Vol. 104, pp. 102651-102651
Closed Access | Times Cited: 1
The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease
Senthilkumar S. Karuppagounder, Hu Wang, Terence Kelly, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 679
Closed Access | Times Cited: 19
Senthilkumar S. Karuppagounder, Hu Wang, Terence Kelly, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 679
Closed Access | Times Cited: 19
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
Viviana Brembati, Gaia Faustini, Francesca Longhena, et al.
Frontiers in Molecular Neuroscience (2023) Vol. 16
Open Access | Times Cited: 18
Viviana Brembati, Gaia Faustini, Francesca Longhena, et al.
Frontiers in Molecular Neuroscience (2023) Vol. 16
Open Access | Times Cited: 18
Single-neuron neurodegeneration as a degenerative model for Parkinson’s disease
Sandro Huenchuguala, Juan Segura‐Aguilar
Neural Regeneration Research (2023) Vol. 19, Iss. 3, pp. 529-535
Open Access | Times Cited: 17
Sandro Huenchuguala, Juan Segura‐Aguilar
Neural Regeneration Research (2023) Vol. 19, Iss. 3, pp. 529-535
Open Access | Times Cited: 17
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease
Yongzhen Miao, Hongrui Meng
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Yongzhen Miao, Hongrui Meng
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies
David Baggett, Alex Olson, Mayur Parmar
Brain Disorders (2024), pp. 100163-100163
Open Access | Times Cited: 6
David Baggett, Alex Olson, Mayur Parmar
Brain Disorders (2024), pp. 100163-100163
Open Access | Times Cited: 6
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
Milton H. Werner, C. Warren Olanow
Movement Disorders (2021) Vol. 37, Iss. 1, pp. 6-15
Open Access | Times Cited: 39
Milton H. Werner, C. Warren Olanow
Movement Disorders (2021) Vol. 37, Iss. 1, pp. 6-15
Open Access | Times Cited: 39
Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases
Wei Liu, Gang Wang, Zhiwen Wang, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1994-2007
Closed Access | Times Cited: 24
Wei Liu, Gang Wang, Zhiwen Wang, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1994-2007
Closed Access | Times Cited: 24
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease
Shijie Wang, Shakthi Unnithan, Nicole Bryant, et al.
Movement Disorders (2022) Vol. 37, Iss. 7, pp. 1454-1464
Open Access | Times Cited: 24
Shijie Wang, Shakthi Unnithan, Nicole Bryant, et al.
Movement Disorders (2022) Vol. 37, Iss. 7, pp. 1454-1464
Open Access | Times Cited: 24
Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease
Ryan R. Walsh, Nitin K. Damle, Sanjay Mandhane, et al.
Parkinsonism & Related Disorders (2023) Vol. 108, pp. 105281-105281
Open Access | Times Cited: 14
Ryan R. Walsh, Nitin K. Damle, Sanjay Mandhane, et al.
Parkinsonism & Related Disorders (2023) Vol. 108, pp. 105281-105281
Open Access | Times Cited: 14
Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
Max Stevenson, Rency S. Varghese, Michaeline Hebron, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Max Stevenson, Rency S. Varghese, Michaeline Hebron, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
Viswanath Das, John H. Miller, Alladi Charanraj Goud, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2078-2111
Open Access | Times Cited: 5
Viswanath Das, John H. Miller, Alladi Charanraj Goud, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2078-2111
Open Access | Times Cited: 5
α-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism
Soumitra Ghosh, Seok Joon Won, Jiejie Wang, et al.
Progress in Neurobiology (2021) Vol. 202, pp. 102070-102070
Open Access | Times Cited: 29
Soumitra Ghosh, Seok Joon Won, Jiejie Wang, et al.
Progress in Neurobiology (2021) Vol. 202, pp. 102070-102070
Open Access | Times Cited: 29
Advances in dementia with Lewy bodies
Melissa J. Armstrong
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 29
Melissa J. Armstrong
Therapeutic Advances in Neurological Disorders (2021) Vol. 14
Open Access | Times Cited: 29
